Navigation Links
NeoPharm Provides Update on LE-SN38 Program

ical trials of the Company's drug product candidates, including, but not limited to, LE-SN38, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, regulatory approval, production, and marketing of the Company's drug and non-drug compounds including, but not limited to the Company's ability to develop a program for commercializing LE-SN38 and its other liposomal technology drug product candidates, the Company's funding of certain of its development projects in order to conserve its cash resources, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug and non-drug compounds, including, but not limited to, LE-SN38 and its other liposomal technology drug product candidates, that could slow or prevent products coming to market, uncertainty regarding the Company's ability to market its drug and non-drug products, including, but not limited to, LE-SN38 and its other liposomal technology drug product candidates, directly or through independent distributors, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual report on Form 10-K for the calendar year ended December 31, 2006. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.

Contact

NEOPHARM, Inc.
Laurence Birch, President and Chief Executive Officer
lbirch@neopharm.com
847-406-1781


'"/>




Page: 1 2

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
7. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
8. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
9. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NeoPharm Provides Update Program
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market ... Scanner Industry, 2009-2019 is a professional and in-depth ... Crystallography Scanner industry . The report firstly reviews ... its classification, application and manufacturing technology. The report ... X-Ray Crystallography Scanner listing their product specification, capacity, ...
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... SAN DIEGO, Oct. 2 Pharmatek Laboratories, Inc., a ... industry, announced that it is the first CRO on ... the company,s preclinical and early phase clinical GMP supply ... move our customers, drug candidates into the clinic more ...
... The next major personalized medicine advances will create therapies that ... health care industry to gain access, the inventor of the ... Medical Center,s Personalized Health Care National Conference ... for Systems Biology, said personalized medicine,s first "killer apps" - ...
Cached Medicine Technology:Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast 2Personalized Medicine 'Killer Apps' Will Transform Care Model 2
(Date:8/29/2014)... As reported by GantDaily.com in the article ... , Outbreaks (8/20), the National Institute on Drug Abuse is ... trends by turning to social media. As NIDA currently relies ... also working with the University of Maryland to create a ... which will be funded by the National Institute of Health. ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by the ... By Drug Court Grad (8/17), a graduate of the Frederick ... back after his own experience with the program. The graduate, Korey ... also includes a 1 mile walk. He plans to donate the ... well as to those who helped him. Shorb, who graduated in ...
(Date:8/29/2014)... 2014 Market Research Report on ... a professional and in-depth market survey on Global ... reviews the basic information of Glass microfiber including ... then explores global and China’s top manufacturers of ... value, and market share etc. , The report ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... G. Rodas. Dr. Rodas will be practicing out of ... As a member of Healthpointe’s orthopedic team, ... internal medicine, and board-certified in occupational medicine. , ... title as Medical Director of Raytheon, the world-class defense ...
(Date:8/29/2014)... Dr. Parsa Mohebi M.D. has developed new techniques ... great results in hair transplantation. One of these techniques ... FUE method that harvests facial hair for transplanting to the ... whose hair loss classification is 5 and above achieve reasonable ... alternative for those advanced hair loss patients who may not ...
Breaking Medicine News(10 mins):Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2
... ... Open in Late 2008, BETHESDA, Md., Feb. 19 Fox ... Living, Inc. (NYSE: SRZ ), continues to thrive during one ... already,been reserved to date and construction on the community is at ...
... revolution taking place,and it,s changing the face of cold-beverage ... that,s more sophisticated than traditional,sodas. Many are looking for ... past, finding a healthy and delicious bottled,drink was no ... are,definitely something to get excited about., "The beverage ...
... CHARLOTTE, N.C., Feb. 19 MedCath Corporation,(Nasdaq: ... has entered into,a new strategic relationship with Solaris ... LLC, will participate in a new venture to ... hospitals, JFK,Medical Center and Muhlenberg Regional Medical Center. ...
... 19 With Presidential,candidates campaigning -- and smiling ... Michael Kosdon has had ample opportunity to,judge their ... has,picked a winner., "I would definitely say ... than Hillary Clinton," says Kosdon, who has,transformed hundreds ...
... Inc., the worldwide leader,in handheld X-ray technologies, today ... available. The NOMAD Pro builds upon,the heritage of ... http://www.newscom.com/cgi-bin/prnh/20080219/LATU057 ), "The NOMAD has forever changed ... an operator to safely stay in the room ...
... medication, error prevention outreach and education for HIMSS attendees wearing custom ... ... BRUNO, Calif., Feb. 19 First DataBank, a leading,provider of drug ... to focus public and industry attention on the,prevention of medication errors. ...
Cached Medicine News:Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 2Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 3Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 4Health News:The Search for Healthier Drinks Turns Up Yerba Mate 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 3Health News:Smiling on the Campaign Trail - Cosmetic Dentist Michael Kosdon Rates the Candidates 2Health News:Aribex Unveils New Handheld Intraoral X-ray System - NOMAD Pro 2Health News:First DataBank Launches Campaign to Focus Public and Industry Attention on Medication Error Prevention 2Health News:First DataBank Launches Campaign to Focus Public and Industry Attention on Medication Error Prevention 3
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
... II (Low Melt), A low temperature ... melting temperature , Optimal for in-gel restriction ... forms a very manageable clear gel that ... Melts at approximately 65°C and remains fluid ...
... Agarose, Molecular Biology Grade, is ... of nucleic acids. It can ... fragments from 0.2 to 40 ... Agarose is tested and certified ...
Medicine Products: